1. Introduction

Artificial Immune-System Accountability is a proposed legal and governance framework for determining responsibility when artificial or engineered immune systems cause harm, fail to protect a person, or produce unintended biological consequences.

The term is not, by itself, a recognised standalone legal doctrine or a settled cause of action. It is better understood as an interdisciplinary concept combining biotechnology law, medical negligence, product liability, bioethics, public health regulation, and environmental protection.

An artificial immune system may refer to several different technologies:

Engineered immune cells: genetically modified cells, such as CAR-T cells, designed to recognise and attack particular targets.

Artificial or synthetic immune mechanisms: engineered biological systems intended to detect pathogens, abnormal cells, or other biological signals.

Computational artificial immune systems: computer algorithms inspired by biological immunity, used in cybersecurity, anomaly detection, or biomedical analysis.

Immune-modulating medical technologies: products that alter immune responses, including certain gene therapies, biologics, and advanced medicinal products.

The applicable law depends on which technology is involved, the type of injury, the parties responsible, and the jurisdiction.

The central question is:

Who is legally accountable when an artificial immune system fails, malfunctions, or causes foreseeable or unforeseeable harm?

Possible responsible parties include developers, manufacturers, clinical investigators, treating doctors, hospitals, research institutions, regulators, and organisations deploying computational systems. Responsibility must be determined from the facts and applicable law rather than automatically attributed to one party.

2. Meaning and objectives of accountability

Artificial immune-system accountability seeks to establish a transparent process for preventing harm, identifying failures, providing remedies, and assigning responsibility.

Its main objectives are:

Safety: Establish appropriate preclinical testing, clinical evaluation, manufacturing controls, and post-treatment monitoring.

Informed consent: Explain material risks, uncertainties, alternatives, and the possibility of unexpected immune reactions.

Traceability: Preserve records of product design, manufacturing batches, genetic modifications, clinical decisions, and adverse events.

Causation: Determine whether an injury resulted from the product, its administration, clinical negligence, or a combination of factors.

Compensation: Provide access to appropriate remedies where legally established responsibility exists.

Continuing oversight: Detect delayed effects, unexpected immune responses, and safety problems emerging after deployment.

These principles are particularly important where an engineered immune intervention may produce effects that are difficult to reverse or that emerge long after treatment.

3. Legal foundations of artificial immune-system accountability in India

India does not have a single, comprehensive statute specifically titled the Artificial Immune-System Accountability Act. Legal responsibility must therefore be assessed under existing legislation, professional standards, regulatory requirements, and judicial precedents.

A. Medical negligence and professional responsibility

Where an artificial immune intervention is administered by a doctor, the doctor must exercise reasonable professional care. The use of advanced technology does not automatically eliminate the clinician's responsibility to assess the patient's condition, interpret relevant evidence, and respond to complications.

Potential negligence may include:

Administering treatment without adequate clinical evaluation.

Ignoring known contraindications or warning signs.

Failing to monitor serious immune-related complications.

Using an unapproved or inadequately validated intervention without lawful justification.

Failing to provide appropriate follow-up care.

The question is not simply whether the treatment failed. It is whether the responsible professional breached the applicable standard of care and whether that breach caused the injury.

B. Product liability

Manufacturers and developers may face liability where an immune-system product is defective, inadequately tested, improperly manufactured, or accompanied by insufficient warnings or instructions.

In India, the Consumer Protection Act, 2019, provides a product-liability framework, subject to its statutory conditions. Depending on the circumstances, claims may also arise under contract, tort law, and applicable medical-device or pharmaceutical regulation.

For example, if an engineered immune-cell product is contaminated during manufacturing, the manufacturer may bear responsibility if the required legal elements are established. If the product is properly manufactured but a clinician administers it negligently, the clinician or hospital may also be responsible.

C. Informed consent and bodily autonomy

Patients should receive information sufficient to make a voluntary decision about treatment. For advanced immune interventions, material information may include:

The intended biological effect and expected benefits.

Known and reasonably foreseeable adverse reactions.

Significant uncertainties in long-term outcomes.

Available alternatives, including conventional treatment where appropriate.

Monitoring requirements and the possibility of additional treatment.

Whether the intervention is experimental or outside its authorised indication.

A signed form does not automatically establish valid consent. The adequacy of the consent process depends on the actual information provided, the patient's capacity and voluntariness, and the applicable legal standard.

D. Regulatory compliance

Depending on the nature of the technology, relevant Indian frameworks may include the Drugs and Cosmetics Act, 1940, applicable rules governing new drugs and clinical trials, the New Drugs and Clinical Trials Rules, 2019, medical-device regulations where applicable, and professional standards governing medical practice.

The exact regulatory pathway depends on whether the intervention is a cell-based therapy, gene therapy, biological product, medical device, research tool, or computational system.

4. Important case laws

The following decisions establish legal principles that can be applied to artificial immune-system disputes. They should not be mistaken for judgments directly deciding liability for every form of artificial immune technology.

Case 1: Jacob Mathew v. State of Punjab (2005)

Supreme Court of India · (2005) 6 SCC 1

Legal issue: When does medical negligence justify legal liability, particularly criminal liability?

Facts and decision: The case arose from allegations concerning medical care and the availability of functioning oxygen equipment in a hospital. The Supreme Court explained the distinction between civil negligence and the higher threshold for criminal negligence by medical professionals.

Indian Kanoon

+1

Legal principle: Medical negligence requires an applicable duty, a breach of that duty, and resulting harm. An adverse medical outcome alone does not establish negligence. Criminal liability requires the relevant degree of gross negligence or rashness under the applicable criminal law.

Application to artificial immune systems: Suppose a patient suffers a severe immune reaction after receiving engineered immune-cell therapy. The mere occurrence of that reaction would not establish the doctor's negligence. A court would examine the clinical circumstances, accepted professional practice, precautions taken, monitoring, and the causal connection between any breach and the injury.

Conversely, ignoring clear warning signs or failing to provide necessary emergency care may support a negligence claim if the legal requirements are met.

Case 2: Samira Kohli v. Dr. Prabha Manchanda (2008)

Supreme Court of India · (2008) 2 SCC 1

Legal issue: Can a doctor perform a substantially different procedure without obtaining the patient's consent?

Facts and decision: The patient consented to a diagnostic procedure but underwent more extensive surgery while under anaesthesia. The Supreme Court examined the scope and validity of consent and held that consent for one procedure does not ordinarily authorise a materially different procedure, subject to genuine emergencies and other applicable exceptions.

Indian Kanoon

+1

Legal principle: A competent patient's right to decide what is done to their body is fundamental to lawful medical treatment. Consent must relate to the treatment actually undertaken, except where a recognised exception applies.

Application to artificial immune systems: A patient who consents to an experimental immune-cell intervention for one purpose has not necessarily consented to a substantially different intervention or an additional procedure. A hospital should not assume that general consent for treatment authorises every subsequent biological intervention.

This case is particularly relevant where the intervention may have lasting effects on immune function, reproductive health, or other aspects of bodily integrity.

Case 3: Vellore Citizens' Welfare Forum v. Union of India (1996)

Supreme Court of India · (1996) 5 SCC 647

Legal issue: How should courts address environmental risks and scientific uncertainty?

Facts and decision: The litigation concerned environmental pollution associated with tanneries in Tamil Nadu. The Supreme Court recognised the precautionary principle and the polluter-pays principle as important elements of Indian environmental law.

PMC

+1

The cited medical-negligence sources above are not the primary authority for this environmental judgment; the case is included here for its established environmental-law significance.

Legal principle: Preventive measures may be justified where there is a serious environmental threat, even when scientific certainty is incomplete. Environmental harm may also trigger responsibility for remediation and compensation under applicable law.

Application to artificial immune systems: If an engineered biological agent or immune-modifying technology presents a credible risk of unintended environmental release, ecological disruption, or effects on non-target organisms, regulators may need to consider containment, monitoring, and preventive safeguards.

However, the environmental precautionary principle does not automatically establish liability for every medical adverse event. Its application depends on the nature of the risk and the relevant legal framework.

Case 4: Yash Charitable Trust v. Union of India (2026)

Supreme Court of India · 2026 INSC 96 · Judgment dated 30 January 2026

Legal issue: Can unproven stem-cell interventions be offered as routine treatment merely because patients or their guardians consent?

Facts and decision: The case concerned the promotion and administration of stem-cell interventions for autism spectrum disorder. The Supreme Court examined the scientific and regulatory status of these interventions, patient autonomy, clinical-trial safeguards, and the responsibilities of healthcare providers and regulators.

Sci API

+1

Legal principle: Patient consent does not, by itself, make an unproven intervention lawful or establish that it meets accepted medical and regulatory standards. Relevant statutory requirements and research safeguards must still be followed.

Application to artificial immune systems: This is particularly important for experimental immune-cell engineering and other advanced biological interventions. A clinic cannot necessarily justify offering an unproven treatment as ordinary clinical care merely by obtaining a patient's signature.

The case also illustrates the accountability of institutions and regulators: the legality of a treatment pathway, the quality of scientific evidence, and compliance with regulatory safeguards are separate questions from whether a patient consented.

Case 5: Indian Council for Enviro-Legal Action v. Union of India (1996)

Supreme Court of India · (1996) 3 SCC 212

Legal issue: Can an organisation responsible for hazardous pollution be required to bear the cost of remedying the resulting damage?

Legal principle: The Supreme Court applied environmental responsibility principles to industrial pollution, supporting the requirement that those responsible for hazardous activities bear the appropriate costs of remediation and compensation. The case is relevant to environmental harm, rather than direct medical treatment liability.

Indian Kanoon

+1

Application to artificial immune systems: If an engineered biological technology causes legally attributable environmental harm, the polluter-pays principle may inform remediation and compensation under the applicable law. This would require evidence of the relevant activity, environmental damage, causation, and the legal basis for responsibility.

The principle should not be treated as a substitute for the separate rules governing patient injury, defective products, or clinical negligence.

5. Allocation of legal responsibility

A practical accountability model separates responsibility according to the stage at which a failure occurs.

These categories can overlap. For example, a manufacturing defect may trigger product liability, while a hospital's failure to detect a preventable problem may support a separate negligence claim.

6. Important legal questions

A. Causation and scientific uncertainty

Immune responses are biologically complex. A patient may suffer harm because of the underlying disease, a known treatment risk, a product defect, a clinical error, or several interacting factors.

Courts may need expert evidence concerning:

The patient's condition before treatment.

The product's design, quality, and approved use.

The timing and nature of the adverse reaction.

Whether clinical precautions were followed.

Whether an alternative cause is more plausible.

Whether the alleged breach materially contributed to the injury.

An adverse event report is important evidence, but it does not automatically prove that the product or clinician caused the event.

B. Long-term effects and continuing duties

Some engineered biological interventions may require prolonged surveillance. Depending on the treatment and applicable standards, accountability may include maintaining records, reporting adverse events, informing patients of newly identified material risks, and providing appropriate follow-up.

A developer or manufacturer may have different continuing duties from a treating physician. Neither should be presumed responsible for every later complication without examining the applicable law and evidence.

C. Privacy and biological data

Artificial immune technologies may involve genomic information, immune profiles, clinical records, and other sensitive personal data. Their collection and use raise questions of lawful processing, confidentiality, access control, retention, and secondary research use.

In India, applicable privacy and data-protection obligations must be assessed alongside medical confidentiality and research-ethics requirements. A data breach may create a distinct legal issue even when the biological treatment itself was properly administered.

7. A practical example

Suppose a hospital administers an engineered immune-cell treatment. The patient subsequently develops a severe inflammatory reaction.

Stage 1: Product assessment

Investigators examine whether the product was appropriately designed, manufactured, tested, labelled, and supplied.

Stage 2: Clinical assessment

The review considers patient selection, informed consent, dosing, monitoring, and compliance with the relevant treatment protocol.

Stage 3: Causation

Medical experts assess whether the reaction was an inherent treatment risk, resulted from a defect, or was worsened by negligent care.

Stage 4: Legal remedy

Depending on the evidence and applicable law, the patient may pursue a negligence claim, a product-liability claim, a consumer remedy, or another legally available form of relief.

The important distinction is that a treatment-related injury does not necessarily prove negligence, while regulatory approval does not automatically immunise every participant from liability.

8. Recommendations for an effective accountability framework

A robust artificial immune-system accountability framework should incorporate the following safeguards:

Risk-based approval: Require evidence proportionate to the intervention's potential severity, persistence, and reversibility.

Independent review: Ensure appropriate scientific and ethics review before human research begins.

Meaningful consent: Disclose material risks, experimental status, alternatives, and uncertainties in language the patient can understand.

End-to-end traceability: Maintain auditable records covering research, manufacturing, administration, and adverse-event investigations.

Clear allocation of duties: Distinguish product-development responsibility from clinical and institutional responsibility.

Post-market surveillance: Establish mechanisms for identifying delayed adverse effects and communicating material safety findings.

Effective remedies: Preserve access to compensation, regulatory complaints, professional discipline, and judicial review where legally available.

Environmental safeguards: Apply suitable containment and monitoring measures where a technology presents a credible risk beyond the treated individual.

These recommendations are proposed governance measures, not a claim that every item is already mandated by one Indian statute.

9. Conclusion

Artificial Immune-System Accountability provides a useful conceptual framework for addressing the legal risks of engineered immunity and related computational technologies. Its central concern is not merely whether an artificial immune system works, but whether its development, approval, administration, and continued use are safe, lawful, transparent, and properly supervised.

The Indian decisions in Jacob Mathew, Samira Kohli, Vellore Citizens' Welfare Forum, and Yash Charitable Trust provide important principles concerning professional negligence, informed consent, precautionary safeguards, and the regulation of experimental biological interventions.

The most important legal conclusion is that responsibility must be assessed across the entire technology lifecycle. Developers, manufacturers, clinicians, institutions, and regulators may have distinct duties, but liability depends on the relevant legal obligation, the evidence of breach, causation, and the remedy available under the applicable law.

Research note: This is a general legal analysis, primarily under Indian law. The phrase “Artificial Immune-System Accountability” is used here as an analytical concept, not as the name of an independently established legal doctrine.